N⁶-(phenylmethoxycarbonyl)-D-lysine-2-phenethylamide | 864738-86-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N⁶-(phenylmethoxycarbonyl)-D-lysine-2-phenethylamide
• 英文别名: benzyl N-[(5R)-5-amino-6-oxo-6-(2-phenylethylamino)hexyl]carbamate
• CAS: 864738-86-3
• 化学式: C₂₂H₂₉N₃O₃
• 分子量: 383.491
• InChiKey: WKZPZNBQOSUNOT-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  93.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N⁶-(phenylmethoxycarbonyl)-D-lysine-2-phenethylamide 在 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N²-[3,5-dibromo-L-tyrosyl]-N⁶-(phenylmethoxycarbonyl)-D-lysine-2-phenethylamide trifluoroacetate
  参考文献：
  名称：

  Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. 1. Potent and Selective Small Molecule CGRP Antagonists. 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine:  The First CGRP Antagonist for Clinical Trials in Acute Migraine

  摘要：

  Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel approach was based on the hypothesis that the release of calcitonin gene-related peptide (CGRP) could play a causative role in migraine headache. Thus we initiated a program aimed at the design and synthesis of small molecule CGRP receptor antagonists. High throughput screening led to the identification of (R)-Tyr-(S)-Lys dipeptide-like compounds that showed weak but unequivocal binding to the human CGRP receptor. Lead optimization afforded highly potent CGRP antagonists, the prototype being compound 19 (BIBN4096). This compound exhibiting a favorable biological profile was selected for initial clinical trials. A proof of concept study indicated that intravenous application of 19 was effective in the treatment of acute migraine headache. This finding strongly supports our initial working hypothesis that CGRP plays an important role in the pathophysiology of migraine.

  DOI：

  10.1021/jm0490641
• 作为产物：
  描述：

  N2-[叔丁氧羰基]-N6-[苄氧羰基]-D-赖氨酸 在 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N⁶-(phenylmethoxycarbonyl)-D-lysine-2-phenethylamide
  参考文献：
  名称：

  Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. 1. Potent and Selective Small Molecule CGRP Antagonists. 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine:  The First CGRP Antagonist for Clinical Trials in Acute Migraine

  摘要：

  Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel approach was based on the hypothesis that the release of calcitonin gene-related peptide (CGRP) could play a causative role in migraine headache. Thus we initiated a program aimed at the design and synthesis of small molecule CGRP receptor antagonists. High throughput screening led to the identification of (R)-Tyr-(S)-Lys dipeptide-like compounds that showed weak but unequivocal binding to the human CGRP receptor. Lead optimization afforded highly potent CGRP antagonists, the prototype being compound 19 (BIBN4096). This compound exhibiting a favorable biological profile was selected for initial clinical trials. A proof of concept study indicated that intravenous application of 19 was effective in the treatment of acute migraine headache. This finding strongly supports our initial working hypothesis that CGRP plays an important role in the pathophysiology of migraine.

  DOI：

  10.1021/jm0490641

文献信息

• Novel N-substituted alpha aminoacid amides as calcium channel modulators
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0805147A1

  公开（公告）日：1997-11-05

  The compounds of formula I and derivatives thereof have been found to be active in tests that show modulation of voltage-dependent calcium channels, and are thus indicated for use in the treatment of diseases in which such modulation is beneficial, in particular diseases of the central nervous system.

  公式I及其衍生物的化合物已被发现在显示调节电压依赖性钙通道的测试中具有活性，因此适用于治疗对此类调节有益的疾病，特别是中枢神经系统疾病。
• N-substituted alpha aminoacid amides as calcium channel modulators
  申请人：ELI LILLY AND COMPANY LIMITED

  公开号：EP1041064A2

  公开（公告）日：2000-10-04

  A pharmaceutical compound having the formula in which R1 is alkyl, -SO2R14 where R14 is alkyl, optionally substituted aryl or optionally substituted heteroaryl, R2 is hydrogen, alkyl optionally substituted with one or more hydroxy or C1-4 alkoxy groups, optionally substituted aryl, optionally substituted heteroaryl, -OR15, -P(O)(OR15)(OR16) or -NR15R16 where R15 and R16 are each hydrogen or alkyl, or -SO2R17 where R17 is hydrogen, alkyl, optionally substituted aryl or optionally substituted heteroaryl, R3 is hydrogen, -CN, -CO2R18, -CONR18R19,-CH18≡CHR19, -C≡CR18, -OCH2CO.R18, -SO2R18, -CH2OR18, -CH2OCO.R18, -CH2NHCOR18, -CH2N(COR18)2, -CHO, -OR18, -CH2NR18R19, -CH2OR18, -CH=NR18 or -CH=N-OR18, where R18 and R19 are each hydrogen or alkyl, X is a bond or -SO2-, R4, R5, R6, R8, R9 and R10 are each hydrogen or alkyl, n is 1 to 4, A is -CH2- or -YCO- where Y is a bond, -O-, optionally substituted phenylene, -CH=CH-, or -NR20- where R20 is hydrogen or alkyl, R7 is the C-α substituent of an amino acid or an ester thereof, or R6 and R7 together form a C3-5 alkylene chain optionally substituted by C1-4 alkyl or hydroxyl, or a group of the formula -CH2-Z-CH2- where Z is -CO-, -S-, -SO- or -SO2-, or R7 and R8 together form a C3 to C5 alkylene chain optionally substituted by C1-4 alkyl or hydroxyl, B is -CON(R21)-, -CON(R21)N(R22)- or where -x=y- is -C(R22)=N-, -N=C(R22)- or -N=N-, where R21 is hydrogen, alkyl or -NR23R24 where R23 and R24 are each hydrogen or alkyl, and where R22 is hydrogen or alkyl, or R8 and R21 together form a C2-4 alkylene chain, m is 0 to 2, R11 is hydrogen or alkyl, R12 is hydrogen, alkyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -OH, -CO2R25, -CONR25R26, where R25 and R26 are each hydrogen or alkyl, and R13 is alkyl, optionally substituted aryl or optionally substituted heteroaryl, or R12 and R13 together form a C3-8 cycloalkyl group or C3-8 cycloalkyl fused to optionally substituted phenyl; or a salt or ester thereof.

  一种药物化合物，其化学式为 其中 R1是烷基、-SO2R14，其中R14是烷基、任选取代的芳基或任选取代的杂芳基、 R2 是氢、任选被一个或多个羟基或 C1-4 烷氧基取代的烷基、任选被取代的芳基、任选被取代的杂芳基、-OR15、 -P(O)(OR15)(OR16)或-NR15R16（其中 R15 和 R16 各为氢或烷基），或-SO2R17（其中 R17 为氢、烷基、任选取代的芳基或任选取代的杂芳基）、 R3 是氢、-CN、-CO2R18、-CONR18R19、-CH18≡CHR19、-C≡CR18、-OCH2CO.R18、-SO2R18、-CH2OR18、-CH2OCO.R18、-CH2NHCOR18、-CH2N(COR18)2、-CHO、-OR18、-CH2NR18R19、-CH2OR18、-CH=NR18 或 -CH=N-OR18，其中 R18 和 R19 各为氢或烷基、 X 是键或-SO2-、 R4、R5、R6、R8、R9 和 R10 各为氢或烷基、 n 为 1 至 4、 A 是-CH2-或-YCO-，其中 Y 是键、-O-、任选取代的亚苯基、-CH=CH-或-NR20-，其中 R20 是氢或烷基、 R7 是氨基酸或其酯的 C-α 取代基，或 R6 和 R7 共同形成任选被 C1-4 烷基或羟基取代的 C3-5 亚烷基链，或式 -CH2-Z-CH2- 的基团，其中 Z 是 -CO-、-S-、-SO- 或 -SO2-、 或 R7 和 R8 共同形成任选被 C1-4 烷基或羟基取代的 C3 至 C5 亚烷基链、 B 是-CON(R21)-、-CON(R21)N(R22)-或 其中-x=y-是-C(R22)=N-、 -N=C(R22)-或-N=N-，其中 R21 是氢、烷基或-NR23R24，其中 R23 和 R24 分别是氢或烷基，R22 是氢或烷基，或 R8 和 R21 共同形成 C2-4 亚烷基链、 m 为 0 至 2、 R11 是氢或烷基 R12 是氢、烷基、任选取代的芳基、任选取代的杂芳基、-CN、-OH、-CO2R25、-CONR25R26，其中 R25 和 R26 各自是氢或烷基，以及 R13 是烷基、任选取代的芳基或任选取代的杂芳基，或 R12 和 R13 共同形成 C3-8 环烷基或与任选取代的苯基融合的 C3-8 环烷基； 或其盐或酯。
• Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. 1. Potent and Selective Small Molecule CGRP Antagonists. 1-[<i>N</i>²-[3,5-Dibromo-<i>N</i>-[[4-(3,4-dihydro-2(1<i>H</i>)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-<scp>d</scp>-tyrosyl]-<scp>l</scp>-lysyl]-4-(4-pyridinyl)piperazine:  The First CGRP Antagonist for Clinical Trials in Acute Migraine
  作者：Klaus Rudolf、Wolfgang Eberlein、Wolfhard Engel、Helmut Pieper、Michael Entzeroth、Gerhard Hallermayer、Henri Doods

  DOI：10.1021/jm0490641

  日期：2005.9.1

  Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel approach was based on the hypothesis that the release of calcitonin gene-related peptide (CGRP) could play a causative role in migraine headache. Thus we initiated a program aimed at the design and synthesis of small molecule CGRP receptor antagonists. High throughput screening led to the identification of (R)-Tyr-(S)-Lys dipeptide-like compounds that showed weak but unequivocal binding to the human CGRP receptor. Lead optimization afforded highly potent CGRP antagonists, the prototype being compound 19 (BIBN4096). This compound exhibiting a favorable biological profile was selected for initial clinical trials. A proof of concept study indicated that intravenous application of 19 was effective in the treatment of acute migraine headache. This finding strongly supports our initial working hypothesis that CGRP plays an important role in the pathophysiology of migraine.